Gaithersburg's OpGen, Inc. (Nasdaq:OPGN), has made a deal to acquire AdvanDx, Inc., a Woburn, Mass. developer of advanced molecular diagnostic products.
AdvanDx is best known for its work in the molecular testing of blood cultures. QuickFISH™ products by AdvanDx provide 20 minute identification and differentiation of Gram-negative species and other blood pathogens.
"The acquisition of AdvanDx strengthens OpGen's portfolio of rapid molecular tests for combating drug resistant infections, while providing additional avenues to sell our Acuitas tests," Evan Jones, Chairman & CEO, said in a statement. "[The] combination of the two companies will expand our revenue and customer base and provide rapid testing capabilities to complement our MDRO gene tests. Together we will be able to combine rapid organism ID capabilities with best in class drug resistance testing."
No comments:
Post a Comment